Page last updated: 2024-12-04

2-oxo-3-methylvalerate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-keto-beta-methylvaleric acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-methyl-2-oxovaleric acid : A 2-oxo monocarboxylic acid that is valeric acid carrying oxo- and methyl substituents at C-2 and C-3, respectively. An alpha-keto acid analogue and metabolite of isoleucine in man, animals and bacteria. Used as a clinical marker for maple syrup urine disease (MSUD). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47
CHEBI ID35932
SCHEMBL ID43232
MeSH IDM0066053

Synonyms (53)

Synonym
einecs 215-955-0
787t50hciv ,
(1)-3-methyl-2-oxovaleric acid
einecs 254-616-1
unii-787t50hciv
2-keto-3-methyl-valeric acid
C03465 ,
1460-34-0
2-oxo-3-methylpentanoic acid
2-oxo-3-methylvaleric acid
2-oxo-3-methyl-n-valeric acid
3-methyl-2-oxopentanoic acid
alpha-keto-beta-methylvaleric acid
ketoisoleucine
CHEBI:35932
3-ethyl-3-methylpyruvic acid
3-methyl-2-oxovaleric acid
K0020
AKOS006220526
FT-0628729
.alpha.-keto-.beta.-methyl-n-valeric acid
dl-3-methyl-2-oxovaleric acid
dl-3-methyl-2-oxo pentanoic acid
.alpha.-keto-.beta.-methylvaleric acid
fema no. 3870, acid-(+/-)-
3-methyl-2-oxovaleric acid, dl-
pentanoic acid, 3-methyl-2-oxo-
dl-3-methyl-2-oxopentanoate
.alpha.-oxo-.beta.-methylvaleric acid
(+/-)-3-methyl-2-oxopentanoic acid
3-methyl-2-oxopentanoic acid [fhfi]
dl-3-methyl-2-oxopentanoic acid
valeric acid, 3-methyl-2-oxo-
dl-3-ethyl-3-methylpyruvic acid
.alpha.-oxo-.beta.-methyl-n-valeric acid
3-methyl-2-oxopentanoic acid, (+/-)-
SCHEMBL43232
W-108131
3-methyl-2-oxopentanoic acid, aldrichcpr
mfcd00002582
AS-58809
39748-49-7
3-methyl-2-oxo-pentanoic acid
FT-0703216
DTXSID50862670
F16679
EN300-1852217
Q23905808
3-methyl-2-oxopentanoicacid
HY-113063
CS-0059473
Z1205493610
SY058109

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" KIV elicited clonic convulsions in a dose-response manner, whereas KIC and KMV did not induce seizure-like behavior."( Pharmacological evidence that alpha-ketoisovaleric acid induces convulsions through GABAergic and glutamatergic mechanisms in rats.
Coitinho, AS; de Bastiani, J; de Mello, CF; Fighera, MR; Lima, TT; Wajner, M, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
branched-chain keto acidAn oxo carboxylic acid in which the parent hydrocarbon chain has one or more alkyl substituents. Derivatives formed from the first step in the metabolism of branched-chain amino acids and can provide important information on animal health and disease.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (24)

PathwayProteinsCompounds
Valine, Leucine, and Isoleucine Degradation2852
beta-Ketothiolase Deficiency2852
2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency2852
Propionic Acidemia2852
3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency2852
Maple Syrup Urine Disease2852
3-Methylcrotonyl-CoA Carboxylase Deficiency Type I2852
3-Methylglutaconic Aciduria Type I2852
3-Methylglutaconic Aciduria Type III2852
Methylmalonate Semialdehyde Dehydrogenase Deficiency2852
Methylmalonic Aciduria2852
Isovaleric Aciduria2852
3-Methylglutaconic Aciduria Type IV2852
3-Hydroxyisobutyric Acid Dehydrogenase Deficiency2852
3-Hydroxyisobutyric Aciduria2852
Isobutyryl-CoA Dehydrogenase Deficiency2852
Isovaleric Acidemia2852
Leucine Biosynthesis816
Isoleucine Biosynthesis1622
Secondary Metabolites: Valine and L-Leucine Biosynthesis from Pyruvate1024
Secondary Metabolites: Leucine Biosynthesis716
2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency2952
Glucosinolate biosynthesis from branched-chain amino acid012
Valine, leucine and isoleucine degradation034

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (45.57)18.7374
1990's14 (17.72)18.2507
2000's24 (30.38)29.6817
2010's5 (6.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.75 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.20%)5.53%
Reviews3 (3.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (95.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]